272 related articles for article (PubMed ID: 33692845)
1. Hippo/TEAD4 signaling pathway as a potential target for the treatment of breast cancer.
Wu Y; Li M; Lin J; Hu C
Oncol Lett; 2021 Apr; 21(4):313. PubMed ID: 33692845
[TBL] [Abstract][Full Text] [Related]
2. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics simulations study of influence of Tyr422Ala mutation on transcriptional enhancer activation domain 4 (TEAD4) and transcription co-activators complexes.
Niu RJ; Zheng QC; Zhang HX
J Theor Biol; 2019 Jul; 472():27-35. PubMed ID: 30978352
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional Enhancer Factor Domain Family member 4 Exerts an Oncogenic Role in Hepatocellular Carcinoma by Hippo-Independent Regulation of Heat Shock Protein 70 Family Members.
Coto-Llerena M; Tosti N; Taha-Mehlitz S; Kancherla V; Paradiso V; Gallon J; Bianco G; Garofoli A; Ghosh S; Tang F; Ercan C; Christofori GM; Matter MS; Droeser RA; Zavolan M; Soysal SD; von Flüe M; Kollmar O; Terracciano LM; Ng CKY; Piscuoglio S
Hepatol Commun; 2021 Apr; 5(4):661-674. PubMed ID: 33860124
[TBL] [Abstract][Full Text] [Related]
5. Structural and Functional Overview of TEAD4 in Cancer Biology.
Chen M; Huang B; Zhu L; Chen K; Liu M; Zhong C
Onco Targets Ther; 2020; 13():9865-9874. PubMed ID: 33116572
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
Juan WC; Hong W
Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
[TBL] [Abstract][Full Text] [Related]
7. TEAD4 as an Oncogene and a Mitochondrial Modulator.
Hsu SC; Lin CY; Lin YY; Collins CC; Chen CL; Kung HJ
Front Cell Dev Biol; 2022; 10():890419. PubMed ID: 35602596
[TBL] [Abstract][Full Text] [Related]
8. YAP/TAZ: a promising target for squamous cell carcinoma treatment.
Dong X; Meng L; Liu P; Ji R; Su X; Xin Y; Jiang X
Cancer Manag Res; 2019; 11():6245-6252. PubMed ID: 31360073
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors.
Holden JK; Cunningham CN
Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29558384
[TBL] [Abstract][Full Text] [Related]
10. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
[TBL] [Abstract][Full Text] [Related]
11. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma.
Hayashi H; Uemura N; Zhao L; Matsumura K; Sato H; Shiraishi Y; Baba H
Front Oncol; 2021; 11():700315. PubMed ID: 34395269
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the Hippo Pathway Transcription Factor TEAD.
Lin KC; Park HW; Guan KL
Trends Biochem Sci; 2017 Nov; 42(11):862-872. PubMed ID: 28964625
[TBL] [Abstract][Full Text] [Related]
13. Hippo Signaling Pathway in Gliomas.
Masliantsev K; Karayan-Tapon L; Guichet PO
Cells; 2021 Jan; 10(1):. PubMed ID: 33477668
[TBL] [Abstract][Full Text] [Related]
14. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer.
Zhao C; Zeng C; Ye S; Dai X; He Q; Yang B; Zhu H
Acta Pharm Sin B; 2020 Jun; 10(6):947-960. PubMed ID: 32642404
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors.
Lu W; Fan M; Ji W; Tse J; You I; Ficarro SB; Tavares I; Che J; Kim AY; Zhu X; Boghossian A; Rees MG; Ronan MM; Roth JA; Hinshaw SM; Nabet B; Corsello SM; Kwiatkowski N; Marto JA; Zhang T; Gray NS
J Med Chem; 2023 Apr; 66(7):4617-4632. PubMed ID: 36946421
[TBL] [Abstract][Full Text] [Related]
16. Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implications.
Sun T; Chi JT
Genes Dis; 2021 May; 8(3):241-249. PubMed ID: 33997171
[TBL] [Abstract][Full Text] [Related]
17. The TEA domain family transcription factor TEAD4 represses murine adipogenesis by recruiting the cofactors VGLL4 and CtBP2 into a transcriptional complex.
Zhang W; Xu J; Li J; Guo T; Jiang D; Feng X; Ma X; He L; Wu W; Yin M; Ge L; Wang Z; Ho MS; Zhao Y; Fei Z; Zhang L
J Biol Chem; 2018 Nov; 293(44):17119-17134. PubMed ID: 30209132
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of TEAD transcription factors in cancer.
Pobbati AV; Kumar R; Rubin BP; Hong W
Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
[TBL] [Abstract][Full Text] [Related]
19. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer.
Lee NH; Kim SJ; Hyun J
Biomedicines; 2021 Mar; 9(4):. PubMed ID: 33808155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
